Innovation Pharmaceuticals Inc (IPIX)

[runninggirl2016]

LR Here's your link for 2020 OM WW cases. It was in a previous post of mine but I guess you didn't want to open it and have your verification.
As for B having to be approved for OM before a Payer Analysis is run. Well I'd have to post an email for that and I'm sure I'd violate something by doing that, but you don't need drug approval to run a Payer Analysis. Successful P2 of B-OM was more than sufficient for potential partners to ask for a Payer Analysis.


Estimates show that the highest incident cases of OM in the 7MM were in the United States, followed by Japan in 2020.
The United States, in 2020, accounted for 596,671, OM incident cases, which are expected to grow during the study period, i.e., 2018-2030.
In the year 2020, the total incident cases of OM in EU5 were 623,424, which are expected to grow during the study period, i.e., 2018-2030.
In the year 2020, the total incident cases of OM in Japan were 260,358, which are expected to grow during the study period, i.e., 2018-2030.


https://www.businesswire.com/news/home/20210707005377/en/Oral-Mucositis-OM-Market-Insight-Epidemiology-and-Market-Forecast-Report-2021-2030---ResearchAndMarkets.com